  We develop and analyze a mathematical model of oncolytic virotherapy in the
treatment of melanoma. We begin with a special, local case of the model, in
which we consider the dynamics of the tumour cells in the presence of an
oncolytic virus at the primary tumour site. We then consider the more general
regional model, in which we incorporate a linear network of lymph nodes through
which the tumour cells and the oncolytic virus may spread. The modelling also
considers the impact of hypoxia on the disease dynamics. The modelling takes
into account both the effects of hypoxia on tumour growth and spreading, as
well as the impact of hypoxia on oncolytic virotherapy as a treatment modality.
We find that oxygen-rich environments are favourable for the use of
adenoviruses as oncolytic agents, potentially suggesting the use of
complementary external oxygenation as a key aspect of treatment. Furthermore,
the delicate balance between a virus' infection capabilities and its oncolytic
capabilities should be considered when engineering an oncolytic virus. If the
virus is too potent at killing tumour cells while not being sufficiently
effective at infecting them, the infected tumour cells are destroyed faster
than they are able to infect additional tumour cells, leading less favourable
clinical results. Numerical simulations are performed in order to support the
analytic results and to further investigate the impact of various parameters on
the outcomes of treatment. Our modelling provides further evidence indicating
the importance of three key factors in treatment outcomes: tumour
microenvironment oxygen concentration, viral infection rates, and viral
oncolysis rates. The numerical results also provide some estimates on these key
model parameters which may be useful in the engineering of oncolytic
adenoviruses.
